DEINOVE SA (ALDEI):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:DEINOVE SA (ALDEI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9372
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Deinove SA (Deinove) is a biotech company that discovers, develops and produces compounds. The company combines its biological assets and its metabolic engineering technology in three fields of application including healthcare, nutrition and cosmetics. Its healthcare application provides research and development on new antibiotics for major medical need and exploits therapeutic properties of other compounds such as carotenoids that can be of useful in the fields of inflammation, skin problems and others. Deinove’s nutrition application develops molecules with dyeing, antioxidant or nutritional properties that are useful for the human diet and animal feed. The company’s cosmetics application is for skincare products, with antioxidant and anti-aging molecules, texturizing agents and others. Deinove is headquartered in Grabels, France.

DEINOVE SA (ALDEI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
DEINOVE SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
DEINOVE SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
DEINOVE SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
DEINOVE SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
DEINOVE SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
DEINOVE SA, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
DEINOVE Enters into Collaboration Agreement with bioMerieux 10
Licensing Agreements 11
Deinove Enters into Option and Licensing Agreement with Redx Pharma 11
Deinove Enters into Licensing Agreement with Naicons 12
Equity Offering 13
DEINOVE Raises USD10 Million in Rights Offering of Shares 13
DEINOVE Raises USD4.1 Million in Second Tranche of Private Placement of Shares 15
DEINOVE Raises USD4.4 Million in First Tranche of Private Placement of Shares 16
Acquisition 17
Deinove Acquires Biovertis and Morphochem 17
DEINOVE SA – Key Competitors 18
DEINOVE SA – Key Employees 19
DEINOVE SA – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Sep 27, 2018: DEINOVE: 2018 half-year consolidated results 21
Mar 29, 2018: DEINOVE: Ambitions Confirmed, Milestones Reached, and Financial Results in Line With the Development Strategy 23
Government and Public Interest 28
Sep 12, 2017: The AGIR project carried out by the DEINOVE group is granted €14.6 million by the ‘Investments for the Future’ Program (IFP) operated by Bpifrance to develop new antibiotics 28
Product News 29
Apr 04, 2018: DEINOVE introduces Phyt-n-Resist, the first pure phytoene for skincare 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
DEINOVE SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
DEINOVE SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
DEINOVE SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
DEINOVE SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
DEINOVE SA, Deals By Therapy Area, 2012 to YTD 2018 8
DEINOVE SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
DEINOVE Enters into Collaboration Agreement with bioMerieux 10
Deinove Enters into Option and Licensing Agreement with Redx Pharma 11
Deinove Enters into Licensing Agreement with Naicons 12
DEINOVE Raises USD10 Million in Rights Offering of Shares 13
DEINOVE Raises USD4.1 Million in Second Tranche of Private Placement of Shares 15
DEINOVE Raises USD4.4 Million in First Tranche of Private Placement of Shares 16
Deinove Acquires Biovertis and Morphochem 17
DEINOVE SA, Key Competitors 18
DEINOVE SA, Key Employees 19
DEINOVE SA, Subsidiaries 20

List of Figures
DEINOVE SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
DEINOVE SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
DEINOVE SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
DEINOVE SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
DEINOVE SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
DEINOVE SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
DEINOVE SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
DEINOVE SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[DEINOVE SA (ALDEI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dai-ichi Life Holdings, Inc.:企業の戦略・SWOT・財務情報
    Dai-ichi Life Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Dai-ichi Life Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Daimler AG (DAI):企業の財務・戦略的SWOT分析
    Daimler AG (DAI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Antilles Oil and Gas NL (AVD):石油・ガス:M&Aディール及び事業提携情報
    Summary Antilles Oil and Gas NL (Antilles) is an upstream oil and gas company that carries out the acquisition and exploration of petroleum and gas properties. The company acquires underperforming assets and re-evaluates to identify untapped recoverable reserves. The company’s operates an exploratio …
  • Ontario Teachers’ Pension Plan:企業の戦略・SWOT・財務情報
    Ontario Teachers' Pension Plan - Strategy, SWOT and Corporate Finance Report Summary Ontario Teachers' Pension Plan - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Petroleo Brasileiro SA (PETR4):電力:M&Aディール及び事業提携情報
    Summary Petroleo Brasileiro SA (Petrobras) is an integrated oil and gas company. Its major businesses include exploration and production, refining, marketing, trade and transportation of oil and gas. The company also conducts biofuel, petrochemical, natural gas, electricity and chemical businesses, …
  • The TJX Companies, Inc.:企業の戦略・SWOT・財務情報
    The TJX Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The TJX Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Dimension Data Holdings Plc:企業の戦略的SWOT分析
    Dimension Data Holdings Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Aerie Pharmaceuticals Inc (AERI):製薬・医療:M&Aディール及び事業提携情報
    Summary Aerie Pharmaceuticals Inc (Aerie) is a pharmaceutical company that discovers, develops and commercializes therapies for the treatment of patients with glaucoma and other diseases of the eye. The company’s product candidates comprise rhopressa, a once-daily eye drop which is used for the redu …
  • MetGen Oy:電力:M&Aディール及び事業提携情報
    Summary MetGen Oy (MetGen) is a manufacturer and distributor of enzymatic solutions. The company offers metzyme, an industrial and natural catalysts used for accelerating chemical reactions. Its enzymatic solutions find applications in various processes such as mechanical processes, lignocellulosic …
  • Veikkaus Oy:企業の戦略的SWOT分析
    Veikkaus Oy - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Oltchim SA (OLT):企業の財務・戦略的SWOT分析
    Summary Oltchim SA (Oltchim) is a chemical company that manufactures and markets petrochemical products. The company offers inorganic, macro molecular and organic synthesis products. Its inorganic products include caustic soda, liquid chlorine, hydrochloric acid and sodium hypochlorite. Oltchim's ma …
  • Nippon Steel & Sumitomo Metal Corp:企業の戦略・SWOT・財務情報
    Nippon Steel & Sumitomo Metal Corp - Strategy, SWOT and Corporate Finance Report Summary Nippon Steel & Sumitomo Metal Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • The Bank Of East Asia, Limited
    The Bank Of East Asia, Limited - Strategy, SWOT and Corporate Finance Report Summary The Bank Of East Asia, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Massilly Holding S.A.:企業の戦略・SWOT・財務分析
    Massilly Holding S.A. - Strategy, SWOT and Corporate Finance Report Summary Massilly Holding S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Sygnis AG (LIO1):医療機器:M&Aディール及び事業提携情報
    Summary Sygnis AG (Sygnis), formerly Sygnis Pharma AG is a developer of novel products and tools in the field of molecular biology. The company undertakes development and marketing of new molecular biological technologies for DNA amplification and sequencing. Its offers products such as single cell …
  • Yokogawa Electric Corporation (6841):企業の財務・戦略的SWOT分析
    Yokogawa Electric Corporation (6841) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Ohio State University Comprehensive Cancer Center:製薬・医療:M&Aディール及び事業提携情報
    Summary Ohio State University Comprehensive Cancer Center (OSUCCC), a subsidiary of Ohio State University, is a healthcare institute that offers medical and academic education services. The institute provides education, research, and patient care services. Its services comprise cancer diagnosis, tre …
  • Prominence Energy NL (SUR):企業の財務・戦略的SWOT分析
    Summary Prominence Energy NL(Prominence Energy) formerly known as Sun Resources NL is an oil and gas exploration and development company. The company explores and develops crude oil and natural gas. Its services include exploration, production, and development of unconventional oil and gas resources …
  • Orient Europharma Co Ltd (4120):企業の財務・戦略的SWOT分析
    Summary Orient Europharma Co Ltd (OEP) is a pharmaceutical company that manufactures and markets prescription medication, Innovative medical and Infant health products. The company’s prescription medication products include cardiovascular medication, immunology medicine, metabolism medicine, neurolo …
  • Central Petroleum Ltd (CTP):企業の財務・戦略的SWOT分析
    Summary Central Petroleum Ltd (CPL) operates as an oil and gas company that offers exploration and development services. The company develops, produces, processes and markets hydrocarbons. It operates its oil and gas assets in Amadeus basin, Pedirka basin, Georgina basin, and Wiso basin. CPL’s Amade …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆